{"article_title": "Enzo Biochem stock tumbles after patent win tossed out", "article_keywords": ["enzo", "appeals", "tossed", "district", "patent", "win", "construction", "low", "infringement", "fell", "ruling", "tumbles", "court", "biochem", "stock"], "article_url": "http://www.healthcarefinancenews.com/news/enzo-biochem-stock-tumbles-after-patent-win-tossed-out", "article_text": "Shares of Farmingdale, New York-based Enzo Biochem fell as low as 17 percent on Tuesday after a federal appeals court threw out a patent infringement ruling it won against Applera.\n\nShares of Farmingdale, New York-based Enzo Biochem fell as low as 17 percent on Tuesday after a federal appeals court threw out a patent infringement ruling it won against Applera, a division of Thermo Fisher Scientific.\n\nThe original $61 million ruling for Enzo claimed Appelera has used patented genetic screening methods by Enzo designed to read genetic code.\n\nBut in its reversal on Monday, judges for the 2nd District U.S. Court of Appeals said it erred in the original verdict.\n\nFollow Healthcare Finance on Twitter and LinkedIn.\n\n\u201cBecause we agree with Applera that the district court erred in its claim construction by finding that the claims at issue covered direct detection, we reverse the district court\u2019s claim construction, vacate the judgment of infringement,\u201d the ruling stated.\n\nEnzo\u2019s patent, \"Modified polynucleotides and methods of preparing same,\" expired in 2004.\n\nWhile investors were clearly shaken by the news, Enzo said it would not accept the ruling and instead requested a retrial over the alleged infringement.\n\n\u201cCounter to the District Court\u2019s construction of the \u2018767 patent as allowing for directly-detectable labels on nucleotides and polynucleotides, and counter to the jury\u2019s verdict that the patent describes such labelling, the Court of Appeals, held such labelling excluded by claim 1 of that patent,\u201d the company said in a statement.\n\nWhile Enzo\u2019s stock had rebounded slightly by late-day trading on the New York Stock Exchange, share prices fell as low as $2.55 per share earlier in the day.\n\nHere\u2019s the full ruling:\n\nTwitter: @HenryPowderly", "article_metadata": {"og": {"url": "http://www.healthcarefinancenews.com/news/enzo-biochem-stock-tumbles-after-patent-win-tossed-out", "image": "http://www.healthcarefinancenews.com/sites/healthcarefinancenews.com/files/wall-street-bull-feature_1.gif", "site_name": "Healthcare Finance News", "description": "Shares of Farmingdale, New York-based Enzo Biochem fell as low as 17 percent on Tuesday after a federal appeals court threw out a patent infringement ruling it won against Applera.", "title": "Enzo Biochem stock tumbles after patent win tossed out"}, "twitter": {"image": {"src": "http://www.healthcarefinancenews.com/sites/healthcarefinancenews.com/files/wall-street-bull-feature_1.gif"}, "description": "Shares of Farmingdale, New York-based Enzo Biochem fell as low as 17 percent on Tuesday after a federal appeals court threw out a patent infringement ruling it won against Applera.", "site": "@HC_Finance", "card": "summary_large_image", "title": "Enzo Biochem stock tumbles after patent win tossed out"}, "generator": "Drupal 7 (http://drupal.org)", "description": "Shares of Farmingdale, New York-based Enzo Biochem fell as low as 17 percent on Tuesday after a federal appeals court threw out a patent infringement ruling it won against Applera, a division of Thermo Fisher Scientific.&#13; The original $61 million ruling for Enzo claimed Appelera has used patented genetic screening methods by Enzo designed to read genetic code.&#13; But in its reversal on Monday, judges for the 2nd District U.S. Court of Appeals said it erred in the original verdict.", "viewport": "width=device-width; initial-scale=1.0; maximum-scale=1.0; user-scalable=no"}, "_id": "\"57477afa6914bd0286fe57f1\"", "article_summary": "Shares of Farmingdale, New York-based Enzo Biochem fell as low as 17 percent on Tuesday after a federal appeals court threw out a patent infringement ruling it won against Applera.\nThe original $61 million ruling for Enzo claimed Appelera has used patented genetic screening methods by Enzo designed to read genetic code.\nShares of Farmingdale, New York-based Enzo Biochem fell as low as 17 percent on Tuesday after a federal appeals court threw out a patent infringement ruling it won against Applera, a division of Thermo Fisher Scientific.\nWhile Enzo\u2019s stock had rebounded slightly by late-day trading on the New York Stock Exchange, share prices fell as low as $2.55 per share earlier in the day.\nBut in its reversal on Monday, judges for the 2nd District U.S. Court of Appeals said it erred in the original verdict."}